Form 4: Biote Corp. Executive Acquires Stock Options
SEC Form 4 Filing
Mary Elizabeth Conlon, General Counsel of Biote Corp., reports acquisition of stock options.
Summary
- Mary Elizabeth Conlon, General Counsel of Biote Corp., filed a Form 4.
- The form reports a transaction on April 1, 2025, where Conlon acquired 178,000 employee stock options with an exercise price of $3.63.
- These options vest over time, with 25% vesting on April 1, 2026, and the remainder vesting in 36 equal monthly installments thereafter, contingent upon continuous service.
- The options expire on March 31, 2035.
- Following the transaction, Conlon directly owns 178,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Future Outlook
The document does not contain any specific forward-looking statements for the company.
Industry Context
This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It provides transparency into the equity-based compensation of key personnel.
Stakeholder Impact
- The granting of stock options aligns the executive's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 04/01/2025 | Date of transaction: acquisition of stock options |
| 04/01/2026 | 25% of the stock options vest |
| 03/31/2035 | Expiration date of the stock options |
| 04/02/2025 | Date of signature on the Form 4 |
Keywords
Form 4, stock options, BTMD, Biote Corp., insider trading, Mary Elizabeth Conlon, General Counsel, securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.